{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:36:38Z","timestamp":1793144198298,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,2,11]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In SURPASS-SWITCH, switching from dulaglutide to tirzepatide resulted in greater improvements in glycemic control and body weight in adults with type 2 diabetes (T2D). This study aimed to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide in adults with T2D in prespecified baseline subgroups from SURPASS-SWITCH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>\n                      This phase IV, randomized, open-label, active-controlled, parallel-group, multicenter, multinational trial included adults with hemoglobin A1c (HbA1c) \u22657.0%\u2009to \u22649.5%, on a stable dose of dulaglutide for at least 6 months, on a stable dose of 0\u20133 oral antihyperglycemic medications for at least 3 months, with stable body weight, and body mass index (BMI) \u226525\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      at screening. Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD. Changes from baseline in HbA1c and body weight at week 40 in baseline subgroups of age (&lt;65, \u226565 years), HbA1c (\u22648.5%, &gt;8.5%), duration of T2D (\u22645, &gt;5\u2009to \u226410, &gt;10 years), baseline dulaglutide dose (0.75 mg, 1.5 mg), duration of dulaglutide dose (&lt;1, \u22651 year), BMI (&lt;27, \u226527; &lt;30, \u226530\u2009to &lt;35, \u226535\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), and ethnicity (Hispanic or Latino, non-Hispanic or non-Latino), and sex (female, male) were determined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups. HbA1c reduction was greater in the subgroups with higher baseline HbA1c and low baseline BMI. Weight reduction was greater for participants in the non-Hispanic or non-Latino subgroup. The safety profile was similar across subgroups. Nausea and diarrhea were usually the most frequently reported treatment-emergent adverse events in each subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this subgroup analysis of SURPASS-SWITCH, switching to tirzepatide from dulaglutide was generally well-tolerated and associated with significant and consistent improvements in HbA1c and weight reductions versus dulaglutide across all baseline subgroups evaluated. These results indicate that switching to tirzepatide may provide a clinical option across a range of baseline characteristics when treatment goals are not being met with dulaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05564039\">NCT05564039<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005711","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:15:11Z","timestamp":1774880111000},"page":"e005711","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05564039","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05564039","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rafael","family":"Violante-Ortiz","sequence":"first","affiliation":[{"name":"Centro de Estudios de Investigaci\u00f3n Metab\u00f3licos y Cardiovasculares, Tampico, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Rose","sequence":"additional","affiliation":[{"name":"Institute of Diabetes Research, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palash","family":"Sharma","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gomez Valderas","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-2779","authenticated-orcid":false,"given":"K Karthik","family":"Chivukula","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita YM","family":"Kwan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026033007150757000_14.2.e005711.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008862"},{"key":"2026033007150757000_14.2.e005711.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026033007150757000_14.2.e005711.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"2026033007150757000_14.2.e005711.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"2026033007150757000_14.2.e005711.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2760"},{"key":"2026033007150757000_14.2.e005711.6","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625"},{"key":"2026033007150757000_14.2.e005711.7","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2759"},{"key":"2026033007150757000_14.2.e005711.8","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2\u2009years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026033007150757000_14.2.e005711.12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","article-title":"A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)","volume":"18","author":"Dungan","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"2026033007150757000_14.2.e005711.15","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1473"},{"key":"2026033007150757000_14.2.e005711.16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/dom.13086","article-title":"Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c","volume":"20","author":"Gallwitz","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.17","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"2026033007150757000_14.2.e005711.19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078"},{"key":"2026033007150757000_14.2.e005711.23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"key":"2026033007150757000_14.2.e005711.24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13300-024-01660-0","article-title":"Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics","volume":"16","author":"De Block","year":"2025","journal-title":"Diabetes Ther"},{"key":"2026033007150757000_14.2.e005711.25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/ANNALS-24-03849","article-title":"Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide\u202f: A Randomized Clinical Trial","volume":"178","author":"Billings","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026033007150757000_14.2.e005711.26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/dom.13896","article-title":"Impact of baseline characteristics and beta\u2010cell function on the efficacy and safety of subcutaneous once\u2010weekly semaglutide: A patient\u2010level, pooled analysis of the SUSTAIN 1\u20105 trials","volume":"22","author":"Aroda","year":"2020","journal-title":"Diabetes Obesity Metabolism"},{"key":"2026033007150757000_14.2.e005711.27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4158\/EP.17.6.906","article-title":"Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program","volume":"17","author":"Henry","year":"2011","journal-title":"Endocr Pract"},{"key":"2026033007150757000_14.2.e005711.28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1507\/endocrj.EJ15-0518","article-title":"Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes","volume":"63","author":"Onishi","year":"2016","journal-title":"Endocr J"},{"key":"2026033007150757000_14.2.e005711.29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/clinem\/dgad495","article-title":"Tirzepatide in Hispanic\/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program","volume":"109","author":"Fr\u00edas","year":"2024","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2026033007150757000_14.2.e005711.30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13353"},{"key":"2026033007150757000_14.2.e005711.31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"The Lancet"},{"key":"2026033007150757000_14.2.e005711.32","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1111\/dom.14533","article-title":"Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11","volume":"23","author":"Frias","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.33","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0872"},{"key":"2026033007150757000_14.2.e005711.34","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/dom.14952","article-title":"Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)","volume":"25","author":"Kiyosue","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/dom.15296","article-title":"Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study","volume":"26","author":"Osonoi","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026033007150757000_14.2.e005711.36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.028381"},{"key":"2026033007150757000_14.2.e005711.37","doi-asserted-by":"crossref","first-page":"107975","DOI":"10.1016\/j.jdiacomp.2021.107975","article-title":"Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data","volume":"35","author":"Boye","year":"2021","journal-title":"J Diabetes Complicat"},{"key":"2026033007150757000_14.2.e005711.38","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2304"},{"key":"2026033007150757000_14.2.e005711.39","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s00125-020-05362-7","article-title":"BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study","volume":"64","author":"Polemiti","year":"2021","journal-title":"Diabetologia"},{"key":"2026033007150757000_14.2.e005711.40","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3097","article-title":"Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States","volume":"35","author":"Aguayo-Mazzucato","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"2026033007150757000_14.2.e005711.41","doi-asserted-by":"crossref","DOI":"10.3390\/ph18091261","article-title":"Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP\/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis","volume":"18","author":"Song","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026033007150757000_14.2.e005711.42","article-title":"Type 2 Diabetes Mellitus in Latinx Populations in the United States: A Culturally Relevant Literature Review","volume":"14","author":"Vidal","year":"2022","journal-title":"Cureus"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:15:15Z","timestamp":1774880115000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjdrc-2025-005711"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005711","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}